RNR Stock Analysis: Renaissancere Holdings | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 13.768m USD | 12M Return: 40.2% | BMG7496G1033 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 127M
EPS Trend: 41.2%
Qual. Beats: 0
Rev. Trend: 67.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RenaissanceRe Holdings Ltd. (RNR) is a Bermuda-based provider of reinsurance and insurance products, operating through two main segments: Property and Casualty & Specialty. The Property segment focuses on catastrophe excess of loss reinsurance, covering events such as hurricanes, earthquakes, typhoons, and terrorism, along with other property products like proportional reinsurance and binding facilities. The Casualty & Specialty segment underwrites a broad portfolio including directors and officers liability, medical malpractice, professional indemnity, workers compensation, cyber, energy, marine, and aviation, among others. The company distributes its products primarily through intermediaries and also invests in and manages funds as part of its operations. Founded in 1993 and headquartered in Pembroke, Bermuda, RenaissanceRe has been listed on the NYSE since 1995.
Reinsurers like RenaissanceRe play a critical role in the broader insurance value chain by enabling primary insurers to offload portions of their risk exposure, particularly for large or catastrophe-level events. Bermuda has historically been a leading global hub for reinsurance companies due to its regulatory framework and tax environment, attracting many of the industrys largest players.
- Property catastrophe reinsurance rates firm following elevated industry losses
- Casualty and Specialty premiums grow on expanded product offerings
- Investment portfolio income rises with sustained higher yields
| Net Income: 2.63b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.59 > 1.0 |
| NWC/Revenue: 76.65% < 20% (prev 268.7%; Δ -192.0% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.61b > Net Income 2.63b |
| Net Debt (-2.92b) to EBITDA (4.54b): -0.64 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.5m) vs 12m ago -13.27% < -2% |
| Gross Margin: 58.56% > 18% (prev 27.81%; Δ 30.75% > 0.5%) |
| Asset Turnover: 19.39% > 50% (prev 23.55%; Δ -4.15% > 0%) |
| Interest Coverage Ratio: 36.14 > 6 (EBIT TTM 4.54b / Interest Expense TTM 125.5m) |
| A: 0.15 (Total Current Assets 19.0b - Total Current Liabilities 10.8b) / Total Assets 55.2b |
| B: 0.20 (Retained Earnings 11.0b / Total Assets 55.2b) |
| C: 0.08 (EBIT TTM 4.54b / Avg Total Assets 55.0b) |
| D: 0.33 (Book Value of Equity 11.8b / Total Liabilities 36.0b) |
| Altman-Z'' = 2.52 = A |
| DSRI: 0.72 (Receivables 8.27b/13.9b, Revenue 10.7b/12.9b) |
| GMI: 0.47 (GM 27.81% / 58.56%) |
| AQI: 4.04 (AQ_t 0.65 / AQ_t-1 0.16) |
| SGI: 0.83 (Revenue 10.7b / 12.9b) |
| TATA: -0.02 (NI 2.63b - CFO 3.61b) / TA 55.2b) |
| Beneish M = -2.06 (Cap -4..+1) = BB |
As of October 17, 2026, the stock is trading at USD 351.06 with a total of 302,576 shares traded. Over the past week, the price has changed by +5.94%, over one month by +6.89%, over three months by +11.49% and over the past year by +40.15%.
Current recommended Stop Loss: 341.00 (which is 2.9% or 1.4 ATR below the current price).
Renaissancere Holdings has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold RNR.
- StrongBuy: 4
- Buy: 0
- Hold: 13
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 347.4 | -1% |
P/E Trailing = 5.7216
P/E Forward = 8.0906
P/S = 1.233
P/B = 1.2233
P/EG = 3.6212
Revenue TTM = 10.7b USD
EBIT TTM = 4.54b USD
EBITDA TTM = 4.54b USD
Long Term Debt = 2.33b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.92b USD (calculated: Debt 2.33b - CCE 5.25b)
Enterprise Value = 10.8b USD (13.8b + Debt 2.33b - CCE 5.25b)
Interest Coverage Ratio = 36.14 (Ebit TTM 4.54b / Interest Expense TTM 125.5m)
EV/FCF = 3.01x (Enterprise Value 10.8b / FCF TTM 3.61b)
FCF Yield = 33.24% (FCF TTM 3.61b / Enterprise Value 10.8b)
FCF Margin = 33.83% (FCF TTM 3.61b / Revenue TTM 10.7b)
Net Margin = 24.71% (Net Income TTM 2.63b / Revenue TTM 10.7b)
Gross Margin = 58.56% ((Revenue TTM 10.7b - Cost of Revenue TTM 4.42b) / Revenue TTM)
Gross Margin QoQ = 60.29% (prev 54.75%)
Tobins Q-Ratio = 0.20 (Enterprise Value 10.8b / Total Assets 55.2b)
Interest Expense / Debt = 5.39% (Interest Expense 125.5m / Debt 2.33b)
Taxrate = 9.92% (437.4m / 4.41b)
NOPAT = 4.09b (EBIT 4.54b * (1 - 9.92%))
Current Ratio = 1.76 (Total Current Assets 19.0b / Total Current Liabilities 10.8b)
Debt / Equity = 0.20 (Debt 2.33b / totalStockholderEquity, last quarter 11.8b)
Debt / EBITDA = -0.64 (Net Debt -2.92b / EBITDA 4.54b)
Debt / FCF = -0.81 (Net Debt -2.92b / FCF TTM 3.61b)
Total Stockholder Equity = 11.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 2.63b / Total Assets 55.2b)
RoE = 22.68% (Net Income TTM 2.63b / Total Stockholder Equity 11.6b)
RoCE = 32.54% (EBIT 4.54b / Capital Employed (Equity 11.6b + L.T.Debt 2.33b))
RoIC = 9.31% (NOPAT 4.09b / Invested Capital 43.9b)
WACC = 5.62% (E(13.8b)/V(16.1b) * Re(5.75%) + D(2.33b)/V(16.1b) * Rd(5.39%) * (1-Tc(0.10)))
Discount Rate = 5.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.01 | Cagr: -9.36%
[DCF] Terminal Value 74.36% ; FCFF base≈3.72b ; Y1≈3.50b ; Y5≈3.26b
[DCF] Fair Price = 1.31k (EV 51.5b - Net Debt -2.92b = Equity 54.4b / Shares 41.6m; r=8.35% [WACC [floored]]; 5y FCF grow -7.46% → 2.50% )
EPS Correlation: 41.24 | EPS CAGR: 9.62% | SUE: 0.59 | # QB: 0
Revenue Correlation: 67.37 | Revenue CAGR: 12.39% | SUE: -0.16 | # QB: 0
EPS current Quarter (2026-09-30): EPS=8.51 | Chg30d=+25.68% | Revisions=+39% | Analysts=17
EPS current Year (2026-12-31): EPS=44.94 | Chg30d=+3.58% | Revisions=+74% | GrowthEPS=+14.9% | GrowthRev=-17.4%
EPS next Year (2027-12-31): EPS=40.05 | Chg30d=+0.93% | Revisions=-17% | GrowthEPS=+1.4% | GrowthRev=-1.1%
[Analyst] Revisions Ratio: +54% (up=27, down=7)